News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Sanofi-Aventis (France) Pulls Obesity Drug Application in U.S.
June 29, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Reuters) - Sanofi-Aventis said on Friday it was withdrawing its application to sell obesity drug rimonabant -- its biggest new drug hope -- in the United States.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Sanofi (France)
MORE ON THIS TOPIC
FDA
Prasad Under Probe for Promoting Workplace Toxicity, Staffers Say
February 27, 2026
·
2 min read
·
Tristan Manalac
Policy
FDA Policy Tracker 2026: One-Trial Drug Applications, Guidelines for Personalized Therapies
February 27, 2026
·
7 min read
·
Heather McKenzie
Regulatory
Makary Defends FDA’s Decision-Making Amid Contentious Rare Disease Rejections
February 27, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Atara Climbs Amid Report of FDA Inconsistency Leading to Cell Therapy’s Rejection
February 26, 2026
·
1 min read
·
Tristan Manalac
